{"id":16759,"date":"2024-12-04T21:14:50","date_gmt":"2024-12-04T13:14:50","guid":{"rendered":"https:\/\/flcube.com\/?p=16759"},"modified":"2024-12-04T21:14:53","modified_gmt":"2024-12-04T13:14:53","slug":"gilead-sciences-secures-exclusive-option-for-tubulis-tubutecan-and-alco5-platforms-to-develop-adc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=16759","title":{"rendered":"Gilead Sciences Secures Exclusive Option for Tubulis’ Tubutecan and Alco5 Platforms to Develop ADC"},"content":{"rendered":"\n

US-based Gilead Sciences Inc., (NASDAQ: GILD<\/a>) has announced an exclusive option and license agreement with Tubulis GmbH, a German firm. This agreement grants Gilead access to Tubulis’ proprietary Tubutecan and Alco5 platforms for the joint development of an antibody-drug conjugate (ADC) targeting solid tumors.<\/p>\n\n\n\n

Financial Terms and Milestones of the Agreement<\/strong>
According to the agreement, Tubulis will receive an upfront payment of USD 20 million. Should Gilead decide to exercise its option, an additional option exercise fee of USD 30 million will be paid. Furthermore, Tubulis is eligible for development and commercialization milestone payments that could reach up to USD 415 million, alongside mid-single to low double-digit tiered royalties on sales of any marketed products emerging from the collaboration.<\/p>\n\n\n\n

Responsibilities and Future Developments<\/strong>
Tubulis will take the lead on early-stage research and development activities for the ADC program. If Gilead chooses to exclusively license the program, it will assume responsibility for all subsequent development and commercialization activities related to the products resulting from this partnership.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Gilead Sciences Inc., (NASDAQ: GILD) has announced an exclusive option and license agreement with…<\/p>\n","protected":false},"author":1,"featured_media":16761,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,226,1025],"class_list":["post-16759","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adc-xdc","tag-gilead-sciences","tag-nasdaq-gild"],"yoast_head":"\nGilead Sciences Secures Exclusive Option for Tubulis' Tubutecan and Alco5 Platforms to Develop ADC - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Gilead Sciences Inc., (NASDAQ: GILD) has announced an exclusive option and license agreement with Tubulis GmbH, a German firm. This agreement grants Gilead access to Tubulis' proprietary Tubutecan and Alco5 platforms for the joint development of an antibody-drug conjugate (ADC) targeting solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=16759\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences Secures Exclusive Option for Tubulis' Tubutecan and Alco5 Platforms to Develop ADC\" \/>\n<meta property=\"og:description\" content=\"US-based Gilead Sciences Inc., (NASDAQ: GILD) has announced an exclusive option and license agreement with Tubulis GmbH, a German firm. This agreement grants Gilead access to Tubulis' proprietary Tubutecan and Alco5 platforms for the joint development of an antibody-drug conjugate (ADC) targeting solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=16759\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-04T13:14:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-04T13:14:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0469.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16759#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16759\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead Sciences Secures Exclusive Option for Tubulis’ Tubutecan and Alco5 Platforms to Develop ADC\",\"datePublished\":\"2024-12-04T13:14:50+00:00\",\"dateModified\":\"2024-12-04T13:14:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16759\"},\"wordCount\":180,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16759#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0469.png\",\"keywords\":[\"ADC \\\/ XDC\",\"Gilead Sciences\",\"NASDAQ: GILD\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16759#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16759\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=16759\",\"name\":\"Gilead Sciences Secures Exclusive Option for Tubulis' Tubutecan and Alco5 Platforms to Develop ADC - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16759#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16759#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0469.png\",\"datePublished\":\"2024-12-04T13:14:50+00:00\",\"dateModified\":\"2024-12-04T13:14:53+00:00\",\"description\":\"US-based Gilead Sciences Inc., (NASDAQ: GILD) has announced an exclusive option and license agreement with Tubulis GmbH, a German firm. This agreement grants Gilead access to Tubulis' proprietary Tubutecan and Alco5 platforms for the joint development of an antibody-drug conjugate (ADC) targeting solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16759#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16759\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16759#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0469.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0469.png\",\"width\":1080,\"height\":608,\"caption\":\"Gilead Sciences Secures Exclusive Option for Tubulis' Tubutecan and Alco5 Platforms to Develop ADC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16759#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences Secures Exclusive Option for Tubulis’ Tubutecan and Alco5 Platforms to Develop ADC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead Sciences Secures Exclusive Option for Tubulis' Tubutecan and Alco5 Platforms to Develop ADC - Insight, China's Pharmaceutical Industry","description":"US-based Gilead Sciences Inc., (NASDAQ: GILD) has announced an exclusive option and license agreement with Tubulis GmbH, a German firm. This agreement grants Gilead access to Tubulis' proprietary Tubutecan and Alco5 platforms for the joint development of an antibody-drug conjugate (ADC) targeting solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=16759","og_locale":"en_US","og_type":"article","og_title":"Gilead Sciences Secures Exclusive Option for Tubulis' Tubutecan and Alco5 Platforms to Develop ADC","og_description":"US-based Gilead Sciences Inc., (NASDAQ: GILD) has announced an exclusive option and license agreement with Tubulis GmbH, a German firm. This agreement grants Gilead access to Tubulis' proprietary Tubutecan and Alco5 platforms for the joint development of an antibody-drug conjugate (ADC) targeting solid tumors.","og_url":"https:\/\/flcube.com\/?p=16759","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-04T13:14:50+00:00","article_modified_time":"2024-12-04T13:14:53+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0469.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=16759#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=16759"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead Sciences Secures Exclusive Option for Tubulis’ Tubutecan and Alco5 Platforms to Develop ADC","datePublished":"2024-12-04T13:14:50+00:00","dateModified":"2024-12-04T13:14:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=16759"},"wordCount":180,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=16759#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0469.png","keywords":["ADC \/ XDC","Gilead Sciences","NASDAQ: GILD"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=16759#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=16759","url":"https:\/\/flcube.com\/?p=16759","name":"Gilead Sciences Secures Exclusive Option for Tubulis' Tubutecan and Alco5 Platforms to Develop ADC - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=16759#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=16759#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0469.png","datePublished":"2024-12-04T13:14:50+00:00","dateModified":"2024-12-04T13:14:53+00:00","description":"US-based Gilead Sciences Inc., (NASDAQ: GILD) has announced an exclusive option and license agreement with Tubulis GmbH, a German firm. This agreement grants Gilead access to Tubulis' proprietary Tubutecan and Alco5 platforms for the joint development of an antibody-drug conjugate (ADC) targeting solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=16759#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=16759"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=16759#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0469.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0469.png","width":1080,"height":608,"caption":"Gilead Sciences Secures Exclusive Option for Tubulis' Tubutecan and Alco5 Platforms to Develop ADC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=16759#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences Secures Exclusive Option for Tubulis’ Tubutecan and Alco5 Platforms to Develop ADC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0469.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16759"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16759\/revisions"}],"predecessor-version":[{"id":16762,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16759\/revisions\/16762"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/16761"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16759"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}